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Abstract
Background: Gastrointestinal stromal tumors (GIST) exhibit an unpredictable clinical course and
can rapidly progress to lethality. Predictions about the biological behavior of GIST are based on a
number of canonical clinical and pathologic parameters whose validity in distinguishing between a
benign and a malignant tumour is still imperfect. The aim of our study was to investigate the role
of morphologic parameters and expression of cells cycle regulators as prognosticators in GIST.
Methods: We performed an immunohistochemical analysis for Ki67, p27Kip1, Jab1, and Skp2, on a
Tissue Microarray (TMA) containing 94 GIST. Expression of the above proteins was correlated to
classically used prognosticators, as well as to risk groups. Clinical significance of histologic and
immunohistochemical features were evaluated in 59 patients for whom follow-up information was
available.
Results: Overexpression of Ki67 and Skp2, and p27Kip1 loss directly correlated with the high risk
group (p = 0.03 for Ki67 and Skp2, p = 0.05 for p27Kip1). Jab1 expression did not exhibit correlation
with risk. In 59 cases provided with clinical follow-up, high cellularity, presence of necrosis, and
Ki67 overexpression were predictive of a reduced overall survival in a univariate model. The same
parameters, as well as mitotic rate, tumour size, and p27Kip1 loss were indicative of a shortened
relapse free survival interval. High cellularity, and high mitotic rate retained their prognostic
significance by multivariate analysis.
Conclusion:  Our data suggest that a number of histologic parameters in combination with
immunohistochemical expression of cell cycle regulators can facilitate risk categorization and
predict biologic behavior in GIST. Importantly this study demonstrates, for the first time, that Skp2
expression correlates with Ki67 expression and high risk in GIST.
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Background
GIST are the most frequent non-epithelial tumors of the
GI tract. They originate from the interstitial cells of Cajal
and are strongly dependent on signaling from the receptor
tyrosine kinase (RTK) KIT and the KIT ligand, stem cell
factor. Activating mutations in KIT and platelet derived
growth factor receptor-A (PDGFRA) result in uncontrolled
proliferation and ultimately trigger the onset of GIST
[1,2]. Mutations in the kit gene in exons 11, 9, 13 and 17
represent early events in GIST onset and have been associ-
ated with malignancy [1,3]. Constitutive activation of
RTKs induces expression and/or phosphorylation of a
variety of intracellular proteins involved in cell survival,
proliferation, and motility and adhesion signals, includ-
ing components of the PTEN/PI3K/AKT pathway [4],
which modulates cell cycle progression by down-regula-
tion of p27Kip1 in various neoplasms. Reduced expression
of PTEN due to mutation is predictive of aggressive dis-
ease in human tumors [5]. Low or absent expression of
PTEN in GISTs has been found to be associated with clin-
ical progression and poor prognosis [6].
Tumour size and mitotic index play a key role in the grad-
ing system for GIST [1,2], although their value in predict-
ing the biological behaviour is limited and all GIST, of any
size, can potentially metastasize. To date no single mor-
phologic, immuno-phenotypic or genetic marker can pre-
dict the aggressiveness of GIST [1].
The risk classification derived from a 2002 NIH consensus
conference provided a means for hierarchical classifica-
tion of aggressiveness into four categories: very low, low,
intermediate and high risk, based on tumour size and
mitotic rate [1]. This classification, while conferring essen-
tial information on prognostic criteria, still needs to be
confirmed by using real follow-up data. In addition, the
consensus criteria over-estimate the biologic potential of
gastric GIST, in particular that of large tumors with low
mitotic rate, as recently reviewed by Miettinen and Lasota
[2]. However in general, gastric tumours have a more
favourable prognosis than intestinal ones with similar
parameters [7].
The proliferation marker Ki67 has proved useful in assess-
ing the rate of tumour cell proliferation in GIST, although
it does not seem to be more reliable than mitotic count
[8]. Uncontrolled cell growth caused by a reduction of lev-
els of cyclin-dependent kinase inhibitors (CKI) is a key
event in human tumour evolution [9]. Loss of p27Kip1 cor-
relates with aggressive potential in human carcinomas
[10], and sarcomas [11], and is an independent prognos-
tic factor in other human tumours [12]. Published evi-
dence suggests a more general deregulation of the cell
cycle in GIST, and we have recently reported that p16INK4A
loss can identify high risk GIST [13], in agreement with
data from a separate study [14]. p27Kip1 loss has been
associated with malignant potential in some reports on
GIST [15-17], although its value as a prognostic marker
has not been conclusively determined in this tumour type
[18]. The human Jun activation-binding protein 1 (Jab1)
has been identified as a p27Kip1 interacting protein, that
induces nuclear export of p27Kip1 to the cytoplasm, thus
permitting its degradation via the ubiquitin-proteosome
pathway [19], and in particular by the activation of the
SCF-Skp2/E3 ubiquitin protein ligase pathway [20]. The
F-Box protein Skp2 functions as the substrate recognition
factor of the SCF complex, which recognizes and binds to
phosphorylated p27Kip1 [21]. Recent findings indicate that
p27Kip1 contributes to Skp2 inhibition via a mechanism
that involves repression of target gene promoter activity,
suggesting a reciprocal regulation between the two pro-
teins [22]. Skp2 overexpression plays a role as an inde-
pendent prognosticator, stronger than p27Kip1 and Ki67,
in soft tissues sarcomas [23]. To the best of our knowl-
edge, its significance as a prognostic marker in GIST has
not been investigated.
The role of Jab1 in human oncogenesis is currently under
investigation. Tomoda et al. showed that Jab1 physically
interacted with p27Kip1  and enhanced its cytoplasmic
translocation, which resulted in accelerated degradation
of p27Kip1 via the ubiquitin/proteasome pathway [19].
Data on human tumours demonstrate that p27Kip1 expres-
sion is inversely correlated to Jab1 expression [24], and
recently Jab1 expression has been demonstrated to induce
p27Kip1 degradation by a Skp2 independent mechanism in
pancreatic carcinoma cells [25].
In this study we have evaluated the significance of histo-
logic parameters and expression of cell cycle regulators in
94 GISTs, 59 of which with clinical information. Our data
confirm the importance of using a mixture of histologic
and immunohistochemical parameters in order to predict
potential benign or malignant behavior in a given GIST at
diagnosis. They also point out to a role for Skp2 and
p27Kip1 as prognostic indicators, in GIST, of good or bad
behavior respectively.
Methods
Clinico-pathologic evaluation
Sample collection, tumour localization, assessment of
behavior, and TMA construction have been described in
detail elsewhere [3]. Two pathologists (DDV and LI) re-
examined representative slides of each tumour. The diag-
nosis of GIST was confirmed in case of a mesenchymal
spindle cell or epithelioid tumour of the GIST showing
unequivocal positivity for CD117. 94 patients met these
criteria and were included in this study. The 94 GIST
patients comprised 50 males and 44 females with a mean
age of 61 years (range 26–91, SD 14). Tumour localiza-BMC Cancer 2008, 8:134 http://www.biomedcentral.com/1471-2407/8/134
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tion involved stomach in 56 (56%), small bowel in 27
(27%), mesentery in seven (7%), duodenum in four
(4%), rectum in three (3%), esophagus in one (1%),
colon in one (1%), abdominal soft tissues in one (1%).
The mean tumour size was 67.3 mm (range 5–250). A
total of 37 tumours (37%) were < 50 mm in diameter. The
assessment of behavior, based upon the categorization
provided by the NIH consensus group in 2002, has been
previously described [3]. Representative large sections of
each tumour were evaluated for the following morpho-
logic criteria: cell type, cellularity, mitotic rate, presence of
tumour necrosis, and of giant cells [26]. In addition the
presence of tumour infiltrating lymphocytes (TIL) was
considered. Cell type was attributed determining the pre-
dominance (> 50%) of spindle, and epitheliod cells. Cel-
lularity was scored, counting the number of cells in
random areas > 0.1 mm2 and considering a number of
100 cells per 10 high-power fields (HPF), as low cellular-
ity (≤ 100 cells) and high cellularity (> 100 cells). Mitoses
were evaluated with mitotic count per 50 high power
fields (HPF), and the cutoff used was 5 mitosis per 50 HPF
according to the 2002 NIH consensus conference [1]. Risk
categories were established using the scheme provided by
Fletcher et al [1], based on tumor size and mitotic count.
The samples were consequently classified in group 0) very
low risk tumours, group 1) low risk tumours; group 2)
intermediate risk tumours, and group 3) high risk and
malignant tumours, respectively. Tumor necrosis and
giant cells were scored as 0–1 depending on their presence
or absence. For TIL a 0–2 score depending on the abun-
dance of lymphocytes infiltrating the neoplasms was
used: 0) absence of lymphocytes; 1) presence of scattered
lymphocytes; 2) grouped (patchy) lymphocytes (Fig. 1E).
Immunohistochemical study
A panel of antibody probes, including antibodies against
KIT (CD117), CD34, Smooth Muscle Actin (SMA),
Desmin, S-100, Neuronal Specific Enolase (NSE), keratin,
and Ki-67 (details in Table 1), were applied to whole sec-
tions of the tumours, using the ABC technique after anti-
gen retrieval. The same markers were examined on the
TMA and displayed good concordance with the whole sec-
tions (data not shown).
Immunohistochemical analysis of cell cycle regulators
p27kip1, Skp2, Jab1 and Ki67 was performed using com-
mercially available antibodies. The conventional avidin-
biotin complex procedure was applied according to the
manufacturer (DAKO, Carpinteria) protocol after optimi-
zation of antigen retrieval. For each antibody only neo-
plastic cells showing definitive nuclear staining were
considered positive and semi-quantitative evaluation was
performed. High nuclear expression of p27kip1, Skp2, and
Ki67 was defined when > 50%, 10%, and 10% of nuclei
were positive, respectively, according to Oliveira et al in
soft tissue sarcomas [23]. For Jab1 we arbitrarily used 10%
as a cutoff of positivity for the purpose of statistical anal-
ysis. The scoring was performed by a single pathologist
(DDV), who had no prior knowledge of the clinical char-
acteristics.
Statistical analysis
Kaplan-Meier curves were used to visualize the histologic
criteria and the protein expression with respect to Overall
Survival (OS) and to Relapse Free Survival (RFS) data at
the univariate level. Log-rank test was used to evaluate sta-
tistical significance of associations. Cox regression analy-
sis was done for multivariate analysis with a stepwise
approach (Wald statistics was applied for entering covari-
ates). Chi-square test and Fisher exact test were used to
evaluate correlations between variables. A p-value < 0.05
was considered significant in all the analysis.
Using the scheme provided by Fletcher et al [1], essentially
based on tumour size and mitotic rate, the tumours were
initially grouped into four categories. Given the limited
number of samples provided with follow-up information,
for both the univariate and multivariate analyses, risk
Morphologic features of GISTs Figure 1
Morphologic features of GISTs. A) Spindle cell tumor 
infiltrating the submucosa and lamina propria of the colon. B) 
Epithelioid cell type tumor. C) Malignant GIST with promi-
nent pleomorphism and high mitotic activity. D) Nuclear pal-
isade feature of GISTs. E) Numerous scattered and patchy 
tumor infiltrating lymphocytes. F) Strong immunoexpression 
of CD 117.BMC Cancer 2008, 8:134 http://www.biomedcentral.com/1471-2407/8/134
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groups were dichotomized to Group A and B, comprising
A) very low and low risk, B) intermediate, high risk, and
malignant tumours. Tumour size was dichotomized
(group 1 ≤ 5 cm, group 2 > 5 cm).
Ethical approval
Institutional Review Board approval was obtained before
the initiation of this study.
Results
Pathological findings
Grossly the tumors were variable in shape. Some were
well circumscribed, firm and whitish, with an irregularly
whorled cut-surface. Others showed ill-defined outlines,
soft or fleshy consistency, with necrotic or hemorrhagic
areas. Microscopically the tumors were categorized as
spindle or epithelioid depending on the most represented
cell type (> 50%) throughout the tumor. Thus 44 tumors
(47%) were predominantly composed of spindle cells
(Fig 1A), 13 tumors (14%) of epithelioid cells (Fig 1B),
and 37 tumors (39%) of both cell types, mixed in variable
proportions. 30 cases of gastric tumors showed the char-
acteristic perinuclear cytoplasmic vacuoles, whereas ske-
noid fibers were seen in 3 tumors located in the small
bowel. Other peculiar histologic features are represented
in Fig. 1C–E. The categorization of risk was as follows: fol-
low-up was available in 59/94 cases. 23 of them were con-
sidered clinically malignant (12 died of disease and 11
were alive with metastatic/recurrent disease). Of the 36
cases with known follow-up remaining, 35 were alive with
disease and 1 was dead for other causes; since the follow-
up was not long enough we pooled them with the 35 cases
for which clinical data were lacking. Of these 71 cases
(36+35) 14 had metastasis at time of diagnosis or later
and therefore were considered also malignant. Therefore
37 cases (23+14) were considered as "malignant". The
remaining 57 cases were categorized according to the NIH
consensus: 12 cases were considered high risk tumours, 19
tumours were intermediate risk, 21 tumours were low
risk, and 5 tumours were categorized as very low risk. Sur-
veys for the presence of tumour-infiltrating lymphocytes
(TIL) revealed a low amount of TIL in 2 tumours, moder-
ate amounts in 28 tumours and numerous TIL in 5
tumours. Of all histological parameters, mitosis (p =
0.001), necrosis (p = 0.02), and tumour size (p < 0.001)
significantly correlated with risk groups dichotomized to
two categories (A & B). The presence of giant cells did not
exhibit any correlation with other parameters.
Immunohistochemical findings
All tumours displayed strong immunoreactivity for
CD117. The staining was localized in the cytoplasm, with
either a granular or homogeneous quality (Fig 1F). Some
differences of immunoreactivity were observed. In partic-
ular, in gastric tumours, CD34, Desmin and Smooth Mus-
cle Actin (SMA) were positive in 98%, 9% and 41% of the
samples respectively; while in extra-gastric tumours, they
were positive in 65%, 0% and 56% of the samples.
Cell cycle protein expression
Detailed results are summarized in Table 2 and Table 3.
Ki67 nuclear expression, higher than 10%, was identified
in 21 tumours (19.7%), and directly correlated with high
risk (p = 0.03). p27Kip1 nuclear expression, in more than
50% of the cells, was detected in 16 tumours (15%) and
was significantly higher in low-risk than in high-risk neo-
plasms (p = 0.04). Skp2 expression was detected in 24
tumours (32%), significantly higher in high risk tumours
(p = 0.03). Representative examples of p27Kip1, Skp2,
Jab1, and Ki67 staining are displayed in Fig 2. Jab1 expres-
sion was detected in 39 (36.6%) of the tumours and did
not exhibit correlation with risk (data not shown). p27Kip1
levels were directly and significantly correlated with Jab1
levels (p < 0.01), and an indirect trend of correlation was
seen with Skp2 levels, even though this was not significant
(data not shown). Interestingly Skp2 expression corre-
lated with cellularity (p = 0.05), tumour size (p = 0.01),
mitotic count (p = 0.05) and Ki67 (p = 0.01) (Table 3).
Table 1: Primary antibodies for immunohistochemical analysis
Antibody Clone Manufacturer Retrieval Dilution Method
CD117 Polyclonal DAKO, Carpinteria, CA, USA Steam 120°/3' Cytrate buffer pH 6 1:300 ABC
CD34 QBEND10 DAKO, Carpinteria, CA, USA Microwave 98°/30' Cytrate buffer pH 6 1:900 ABC
CK22 Cytokeratin Biomeda, san Francisco, CA, USA Microwave 98°/30' Cytrate buffer pH 6 1:400 ABC
Desmin D33 DAKO, Carpinteria, CA, USA Cook 15' Cytrate buffer pH 6 1:200 ABC
SMA 1A4 Sigma, Saint Louis, MO, USA Microwave 80°/30' Cytrate buffer pH 6 1:60000 ABC
S-100 Polyclonal DAKO, Carpinteria, CA, USA Microwave 80°/30' Cytrate buffer pH 6 1:10000 ABC
NSE BBS/NC/VI DAKO, Carpinteria, CA, USA Cook 15' Cytrate buffer pH 6 1:8000 ABC
Ki67 MIB-1 DAKO, Carpinteria, CA, USA Microwave 98°/60' Cytrate buffer pH 6 1:16000 ABC
p27Kip1 57 BD Transduction Laboratories, Lexington KY, USA Microwave 98°/60' Cytrate buffer pH 6 1:500 ABC
Jab-1 Polyclonal Santa Cruz Biotechnology, Santa Cruz, CA, USA Microwave 98°/60' Cytrate buffer pH 6 1:200 ABC
Skp2 2C8D9 Zymed LAB, San Francisco, CA, USA Microwave 98°/60' Cytrate buffer pH 6 1:100 ABCBMC Cancer 2008, 8:134 http://www.biomedcentral.com/1471-2407/8/134
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Clinico-pathological correlations and prognosis (Survival 
analysis)
The median follow-up period for the patients with GIST
was 46 months (maximum 177, minimum 4). Medical
charts were available in 59 cases of 94 patients (63%). Of
these 59 patients, 11 (19%) died of disease, and 12 (21%)
were alive with recurrent/metastatic disease. These 23
tumours were considered clinically malignant. An addi-
tional 35 patients (60%) were alive without disease, and
1 (2%) died from other causes. Univariate analysis was
performed for patient age, tumour localization in the GI
tract, tumour size, cellularity, cell type, mitosis, necrosis,
risk grade, p27Kip1, Skp2, Jab1 and Ki67 expression. Of the
above parameters, we found that necrosis (p = 0.01), high
cellularity (p = 0.04) and Ki67 overexpression (p = 0.04)
were significantly associated with reduced overall survival
(OS). The best multivariate model included cellularity (p
= 0.02) (data not shown). Cellularity (p = 0.01), mitosis
(p < 0.001), tumour size (p = 0.01), high risk (p = 0.01),
Ki67 (p = 0.02), and p27Kip1 (p = 0.05) were significantly
associated with reduced relapse free survival (RFS), by
univariate analysis, as showed in Table 4. The Kaplan-
Meier curves relative to cellularity and Ki67 expression are
represented in Fig 3 and 4 respectively. TIL was associated
with RFS, approaching statistical significance (data not
shown).
Discussion
Our results, on a TMA containing 94 primaries GIST, show
that morphological parameters and immunohistochemi-
cal markers, alone and in combination, may be useful in
predicting benign or malignant biologic behavior of GIST
at diagnosis. In particular, our analysis of 59 cases, for
which clinical information was available, suggests 1) an
independent role for high cellularity in predicting reduced
OS; 2) a significant correlation of cellularity, mitosis,
tumour size, high risk, Ki67 expression, and p27Kip1
expression with RFS; 3) a direct correlation of p27Kip1 loss
as well as of Ki67 and Skp2 over expression with high risk;
and 4) a significant correlation between Ki67 over expres-
sion and OS.
High cellularity, mitosis, and tumour size have been dem-
onstrated to be prognostic factors in separate studies
[2,8,27]. Our results confirm the validity of the above clas-
sical morphological parameters in attributing potentially
malignant behaviour to a given tumour.
We also analyzed the tumours for the presence of TIL. We
found a trend toward an inverse correlation between the
presence of TIL and shortened RFS. TIL are the primary
immune component infiltrating solid tumours and are
considered to be a manifestation of the host anti-tumour
reaction. To the best of our knowledge this feature, only
analyzed in one recent report [28], has not been identified
as a histologically significant indicator in GIST. Our data
not only suggest a role for TIL in an anti-tumour reaction,
but also suggest further investigation on additional series,
into whether GIST patients might be identified who could
benefit from immunotherapy.
In our study, Ki67 over-expression significantly correlated
with high risk and with both OS and RFS. These data are
in apparent contradiction with a study attributing a
stronger potential to mitotic rate than Ki67 index as a
prognosticator in GIST [15], however they are consistent
with other studies in which Ki67 labeling index (LI) dis-
criminated between potentially benign and malignant
GIST better than counts of mitotic figures [8]. The direct
correlation between expression of Ki67 and Skp2 was sig-
nificant, in agreement with what has been found in sev-
eral tumour types, including mesenchymal neoplasms
[23,29,30].
Table 3: Correlation between morphologic criteria and cell cycle 
regulators.
VARIABLE p27Kip1 Ki67 Skp2
Cellularity 1 < 0.001a 0.05a
Mitotic count 0.34 0.01a 0.05a
Necrosis 0.26 0.08 0.82
Risk groups (A&B) 0.04a 0.03a 0.03a
Tumor size 0.27 0.64 0.01a
a Statistically Significant
Table 2: Clinicopathologic parameters and risk categories
Group A Group B
N° cases 26 68
Sex M 15 33
F1 1 3 5
Cell type Spindle 8 36
Epithelioid 4 9
Mixed 14 23
Cellularity Low 15 13
High 11 55
Necrosis 0 26 48
10 2 0
Mitosis 1 21 47
25 2 1
Metastases 1 22
p27Kip1 (%) 9/26 (34.6%) 7/50 (14%)
Skp2 (%) 4/25 (16%) 20/50 (40%)
Jab1 (%) 16/25 (64%) 23/48 (47.9%)
Ki67 (%) 3/25 (12%) 18/52 (34.6%)
Necrosis: 0 = absent; 1 = present
Mitosis: 1 ≤ 5 × 50 HPF; 2 > 5 × 50 HPF
Cellularity: Low cellularity ≤ 100 tumor cells × 10 HPF; High 
cellularity > 100 tumor cells × 10 HPFBMC Cancer 2008, 8:134 http://www.biomedcentral.com/1471-2407/8/134
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In this study p27Kip1 loss was significantly correlated with
the degree of malignancy of GIST. The role of p27Kip1
expression as a diagnostic or prognostic marker for a
broad series of human tumours is currently under intense
investigation. Our results are in agreement with a number
of published studies [16,31,32]. In particular Gelen et al.
demonstrated that p27Kip1 expression is correlated to RFS
[31]. p27Kip1 loss has not been conclusively associated
with biological aggressiveness of GIST, and is not used as
a predictor of survival [15,17,18]. Our results, obtained
on a larger series, show an association between p27Kip1
loss and RFS, suggesting an important role for p27Kip1 in
the progression of GIST, and urging further investigation
of its potential as a prognostic marker.
Cell cycle progression in mammalian cells is finely regu-
lated by the sequential activation of a cascade of cyclin-
dependent kinases, which are modulated by a complex
series of interactions between cyclins and cyclin-depend-
ent kinases inhibitors (CKIs). p27Kip1 is a specific CKI
present at high abundance in quiescent cells and is a puta-
tive tumour suppressor [11,33]. While loss of function of
tumour suppressors occurs frequently at the genetic level,
p27Kip1 mutations represent an extremely rare event, con-
sistent with data that p27Kip1 expression is regulated at the
post-transcripitonal level [34].
In our study, Skp2 expression significantly correlated with
cellularity, high risk, tumour size, mitotic count, and Ki67
expression. To our knowledge, the significance of Skp2
over-expression as a prognostic marker in GIST has not
been previously investigated. We found an inverse corre-
lation between levels of Skp2 and p27Kip1, which
approached the statistical significance. These data are in
agreement with studies on lymphomas [35] and colorec-
tal cancer [10] and suggest that over-expression of Skp2
contributes to p27Kip1 degradation in GIST. Our data are
Table 4: Univariate analysis of various parameters for Overall 
Survival (OS) and Release Free Survival (RFS).
VARIABLE OS RFS
Cell Type 0.42 0.27
Cellularity 0.04a 0.00a
Mitotic count 0.09 0.00a
Necrosis 0.01a 0.14
Risk groups (A&B) 0.07 0.01a
Tumor size 0.13 0.01a
p27Kip1 0.42 0.05
Ki67 0.04a 0.02a
Skp2 0.43 0.5
a Statistically Significant
Composite figure of immunohistochemical staining showing p27Kip1 negativity and strongly positive Skp2, Ki67, and Jab1 Figure 2
Composite figure of immunohistochemical staining showing p27Kip1 negativity and strongly positive Skp2, 
Ki67, and Jab1.BMC Cancer 2008, 8:134 http://www.biomedcentral.com/1471-2407/8/134
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in contrast with findings by Oliveira et al [23] in soft tis-
sues sarcomas, which suggest the possibility of an alterna-
tive mechanism for p27Kip1 degradation in sarcomas. Skp2
over-expression plays a role in aggressiveness of soft tis-
sues sarcomas, where it has been found to be an inde-
pendent prognosticator, stronger than p27Kip1 and Ki67
[23]. In our study, Skp2 over-expression did not correlate
with OS and RFS. However, the correlation of Skp2
Ki67 Kaplan-Meier analysis with respect to overall survival and relapse free survival, respectively Figure 4
Ki67 Kaplan-Meier analysis with respect to overall survival and relapse free survival, respectively. The p-value of 
the log-rank test is reported for each curve.
Kaplan-Meier curves of cellularity with respect to overall survival and relapse free survival, respectively Figure 3
Kaplan-Meier curves of cellularity with respect to overall survival and relapse free survival, respectively. The p-
value of the log-rank test is reported for each curve.BMC Cancer 2008, 8:134 http://www.biomedcentral.com/1471-2407/8/134
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expression with several parameters of malignant potential
(cellularity, high risk, tumour size, mitotic count, and
Ki67 expression) suggests an important auxiliary role of
Skp2 in predicting the aggressive potential of GIST.
The role of Jab1 in human oncogenesis is currently under
investigation. Recently Jab1 expression, inversely corre-
lated to p27Kip1 expression in pancreatic carcinoma and
has been demonstrated to induce p27Kip1 degradation by
a Skp2-independent mechanism [25]. In our series, Jab1
expression did not correlate with any of the other param-
eters we analyzed, including p27Kip1 expression, suggest-
ing that degradation of p27Kip1 in GIST might be Jab1-
independent. It would be interesting to test this hypothe-
sis using in vitro systems.
Conclusion
We demonstrated in the current study that p27Kip1 loss
and Skp2 over-expression correlate with high risk grade in
GIST. Additional studies are necessary to clarify their role
as prognostic indicators.
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